BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Uroplasty, Inc. (UPI) to Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results on May 30, 2013


5/21/2013 6:30:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MINNEAPOLIS, May 20, 2013 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI) announced today that it will release financial results for the fiscal fourth quarter and full year ended March 31, 2013 at the market close on Thursday, May 30, 2013. The Company will host a conference call and webcast to discuss these results on Thursday, May 30, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Individuals wishing to participate in the conference call should dial 888-549-7750, no passcode is necessary. To access the live webcast of the call, go to Uroplasty's website at www.uroplasty.com and click on Investor Relations.

An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4618943#. An archived webcast will also be available at www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Contact Information:




Uroplasty, Inc.

EVC Group

Medi Jiwani, Vice President, CFO, and Treasurer

Jenifer Kirtland (Investors)

952.426.6140

415.568.9349


Amy Phillips (Media)


412-327-9499





SOURCE Uroplasty, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES